Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008.

Journal Article (Journal Article)

PURPOSE: To examine associations between newly diagnosed neovascular age-related macular degeneration and direct medical costs. METHODS: This retrospective observational study matched 23,133 Medicare beneficiaries diagnosed with neovascular age-related macular degeneration between 2004 and 2008 with a control group of 92,532 beneficiaries on the basis of age, sex, and race. The index date for each case-control set corresponded to the first diagnosis for the case. Main outcome measures were total costs per patient and age-related macular degeneration-related costs per case 1 year before and after the index date. RESULTS: Mean cost per case in the year after diagnosis was $12,422, $4,884 higher than the year before diagnosis. Postindex costs were 41% higher for cases than controls after adjustment for preindex costs and comorbid conditions. Age-related macular degeneration-related costs represented 27% of total costs among cases in the postindex period and were 50% higher for patients diagnosed in 2008 than in 2004. This increase was attributable primarily to the introduction of intravitreous injections of vascular endothelial growth factor antagonists. Intravitreous injections averaged $203 for patients diagnosed in 2004 and $2,749 for patients diagnosed in 2008. CONCLUSION: Newly diagnosed neovascular age-related macular degeneration was associated with a substantial increase in total medical costs. Costs increased over time, reflecting growing use of anti-vascular endothelial growth factor therapies.

Full Text

Duke Authors

Cited Authors

  • Qualls, LG; Hammill, BG; Wang, F; Lad, EM; Schulman, KA; Cousins, SW; Curtis, LH

Published Date

  • April 2013

Published In

Volume / Issue

  • 33 / 4

Start / End Page

  • 854 - 861

PubMed ID

  • 23296047

Electronic International Standard Serial Number (EISSN)

  • 1539-2864

Digital Object Identifier (DOI)

  • 10.1097/IAE.0b013e31826f065e


  • eng

Conference Location

  • United States